Jefferies Financial Group provided a buy rating and price target for Hemab Therapeutics.
1 report, 1 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies Financial Group provided a buy rating and price target for Hemab Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Analyst reports are affecting stock price targets for various companies, with company data being summarized on financial blogs.Also in this story
- Jefferies Financial Group restated its buy rating on Paylocity, while Truist Financial cut its target price.
- Financial firms including Bank of America, Morgan Stanley, and Truist Financial adjusted price targets and ratings for Somnigroup International Inc.
- Truist Financial issued a buy rating for a company, with MarketBeat providing average rating data.
- Analyst firms provided research reports and aggregated market data for Sensata Technologies.
The entities involved
-
Jefferies Financial Group
American financial services company
-
MarketBeat
American personal finance blog
Related events
- MarketBeat summarized current ratings and price targets for Arcturus Therapeutics.
- MarketBeat reported consensus price targets and analyst ratings for TScan Therapeutics and Mereo BioPharma Group.
- MarketBeat provided an average rating and target price for Tenaya Therapeutics.
- MarketBeat provided consensus price targets and ratings for Liquidia and Ovid Therapeutics.
- Larimar Therapeutics received new analyst coverage from Citigroup, which reiterated a buy rating, alongside market data updates.